Met Life Investment Management, LLC Passage Bio, Inc. Transaction History

Met Life Investment Management, LLC

  • $17.1 Billion
  • Q3 2024

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 12, 2022
SELL
$2.66 - $6.49 $28,541 - $69,637
-10,730 Closed
0 $0
Q4 2021

Jun 21, 2023
BUY
$6.24 - $10.2 $66,955 - $109,445
10,730 New
10,730 $68,000
Q3 2021

Jun 21, 2023
BUY
$9.73 - $15.52 $104,402 - $166,529
10,730 New
10,730 $106,000
Q2 2021

Jun 21, 2023
BUY
$12.44 - $19.45 $133,481 - $208,698
10,730 New
10,730 $142,000
Q1 2021

May 17, 2024
BUY
$16.24 - $29.83 $174,255 - $320,075
10,730 New
10,730 $187,000
Q1 2021

Jun 26, 2023
BUY
$16.24 - $29.83 $174,255 - $320,075
10,730 New
10,730 $188 Million
Q4 2020

May 24, 2024
BUY
$14.28 - $29.73 $55,949 - $116,482
3,918 Added 57.52%
10,730 $274,000
Q4 2020

Jun 22, 2023
BUY
$14.28 - $29.73 $153,224 - $319,002
10,730 New
10,730 $274,000
Q4 2020

Mar 22, 2023
BUY
$14.28 - $29.73 $55,949 - $116,482
3,918 Added 57.52%
10,730 $274,000
Q4 2020

Feb 16, 2021
BUY
$14.28 - $29.73 $55,949 - $116,482
3,918 Added 57.52%
10,730 $274,000
Q3 2020

Jun 26, 2023
BUY
$12.39 - $26.15 $84,400 - $178,133
6,812 New
6,812 $89,000
Q2 2020

May 24, 2024
BUY
$14.59 - $36.07 $99,387 - $245,708
6,812 New
6,812 $186 Million
Q2 2020

Jun 26, 2023
BUY
$14.59 - $36.07 $99,387 - $245,708
6,812 New
6,812 $186,000
Q2 2020

Mar 22, 2023
BUY
$14.59 - $36.07 $99,387 - $245,708
6,812 New
6,812 $186,000
Q2 2020

Aug 14, 2020
BUY
$14.59 - $36.07 $99,387 - $245,708
6,812 New
6,812 $186,000

Others Institutions Holding PASG

# of Institutions
47
Shares Held
38.7M
Call Options Held
7.7K
Put Options Held
0
View Full List

About Passage BIO, Inc.

PASG Quotes by TradingView
  • Ticker PASG
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 54,463,200
  • Market Cap $25.6M
  • Description
  • Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 ...
More about PASG
Track This Portfolio

Track Met Life Investment Management, LLC Portfolio

Follow Met Life Investment Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Met Life Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Met Life Investment Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email